Cresset Asset Management LLC Has $2.24 Million Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Cresset Asset Management LLC boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 5.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 175,558 shares of the biopharmaceutical company’s stock after purchasing an additional 8,539 shares during the period. Cresset Asset Management LLC’s holdings in Dynavax Technologies were worth $2,242,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in Dynavax Technologies during the 4th quarter worth $990,000. Nordea Investment Management AB raised its position in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares during the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at $275,000. Barclays PLC boosted its holdings in Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its position in Dynavax Technologies by 97.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company’s stock worth $3,964,000 after purchasing an additional 153,302 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Trading Down 2.9 %

DVAX opened at $9.41 on Friday. The firm’s fifty day moving average is $12.24 and its two-hundred day moving average is $12.55. The firm has a market cap of $1.15 billion, a PE ratio of 52.28 and a beta of 1.26. Dynavax Technologies Co. has a twelve month low of $9.28 and a twelve month high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DVAX. The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research note on Thursday, April 17th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities dropped their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.